First Observation of HIV Type 1 Drug Resistance Mutations in Algeria

Bouzeghoub, Salima; Jauvin, Valérie; Recordon-Pinson, Patrícia; Schrive, Marie Hélène; Jeannot, Anne Cecile; Amrane, Abdesalam; Masquelier, Bernard; Belabbes, El Hadj; Fleury, Hervé

doi:10.1089/aid.2008.0087

Cited by 4 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we observed a prevalence of 31% of HIV-1 resistance-associated mutations, 15% considering the list established by Bennett et al 12 : this was a huge increase compared to the previous analysis. 6 Nevertheless, this result is not surprising and has already been observed elsewhere. [9][10][11] In Africa, the prevalence of drug resistance mutations varies across countries, reaching 54.9% in Central Africa.…”

Section: Discussionsupporting

confidence: 74%

“…In previous studies published in 2006 and 2008, we observed high HIV-1 diversity in Algeria with a predominance of the B subtype followed by CRF02_AG and CRF06_cpx. 5,6 In the current study, the diversity was maintained, but CRF06_cpx became widely predominant. The evolution of the HIV infection, previously originating primarily in Europe and now from others neighboring countries, surely explains this epidemiological change.…”

Section: Discussionmentioning

confidence: 50%

“…In previous studies 5,6 we observed a high diversity of HIV type 1 in Algeria, with a complicated pattern of subtypes and circulating recombinant forms (CRFs), particularly in the southern part of the country. Although the B subtype was predominant, CRF06_cpx and CRF02_AG were widely represented.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013–2014

Abdellaziz

Papuchon

Khaled

et al. 2016

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Since 2008, no data on HIV diversity or the transmission rate of HIV resistance mutations in naive patients have been presented for Algeria, a country of MENA region. Between 2013 and 2014, we studied 152 samples including 89 naive patients. The current study describes the change in HIV diversity in Algeria with the predominance of CRF06_cpx and the huge increase of transmitted HIV resistance, which now reaches 15%.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013–2014

Abdellaziz

Papuchon

Khaled

et al. 2016

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…Drug resistance mutations to NRTIs and PIs have been reported in untreated patients in Algeria [21]. Moreover, HIVDR to NRTIs, NNRTIs, and PIs were described in Morocco among ART-naive patients [22].…”

Section: Introductionmentioning

confidence: 99%

Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon

Mokhbat

Melhem

El‐Khatib

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Antiretroviral therapy (ART) has been successful at decreasing the morbidity and mortality associated with human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 drug resistance (HIVDR) among ART-naive patients has been documented to compromise the success of initial therapy. This study was conducted to determine the prevalence of HIVDR mutations among newly diagnosed drug-naive HIV-infected individuals in Lebanon. Methodology: Plasma samples from 37 newly diagnosed participants at various stages of HIV-1 infection were used to determine HIV-1 RNA viral load, isolate viral RNA, and amplify DNA by RT-PCR. Purified PCR products were used to perform genotypic resistance tests. Results: The prevalence of resistance mutations to nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRT), and protease inhibitors (PI) were 5.4%, 10.8%, and 8%, respectively. The major mutations detected in the study participants conferred resistance to NRTIs and NNRTIs recommended for HIV-1 treatment. No significant relationship between HIV-1 viral load of participants and the mode of HIV-1 transmission or between the occurrence of HIVDR and the mode of transmission was found. Conclusions: To our knowledge, this is the first study on HIVDR mutations among newly diagnosed HIV-infected persons in Lebanon. The overall prevalence of HIVDR mutations detected in our study was 16%. Our results are important for evaluating the utility of the standard first-line regimens in use, determining the feasibility of HIVDR testing before the initiation of ART, as well as minimizing the emergence and transmission of HIVDR.

show abstract

HIV Care in the Arab World

Dib¹,

Mokhbat²

2021

Handbook of Healthcare in the Arab World

View full text Add to dashboard Cite

First Observation of HIV Type 1 Drug Resistance Mutations in Algeria

Cited by 4 publications

References 1 publication

Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013–2014

Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013–2014

Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon

HIV Care in the Arab World

Contact Info

Product

Resources

About